A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

NCT05767047

Status	RECRUITING
Phase	Phase 3
Sponsor	Amgen
Enrollment	48 participants

Key Eligibility Criteria

Inclusion (5)

- Informed consent / assent obtained
- Must have completed Week 52 on treatment on core study and must be \< 18 years of age at the time the informed consent document is signed
- Age and sex specific body mass index (BMI) no lower in range than the 5th percentile on Centers for Disease Control (CDC growth chart) at enrollment
- Willing to adhere to study visit schedule and protocol requirements
- Must have acceptable benefit/risk for continued treatment with apremilast

Exclusion (6)

- Answer "yes" to any question on C-SSRS at Week 52 visit of core study
- Scheduled surgery or other interventions that would interrupt study participation
- Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for 30 days after last dose
- Female participants planning to become pregnant while on study through 30 days after last dose
- Female participants of childbearing potential with positive pregnancy test at Week 0

... and 1 more (see full listing online)

Locations (7 total)

General Hospital of Thessaloniki Ippokrateio, Thessaloniki, Greece
Meir Medical Center, Kfar Saba, Israel
Hospital Universitari i Politecnic La Fe, Valencia, Valencia, Spain
... and 4 more locations